Taxotere Approved in Canada for Advanced Breast Cancer and NSCLC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) has received approval from the Canadian Health Protection Branch for use as second-line treatment of advanced breast and non-small-cell lung cancer (NSCLC). The new drug submission was based on clinical trials involving more than 800 patients worldwide.

COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel)has received approval from the Canadian Health Protection Branchfor use as second-line treatment of advanced breast and non-small-celllung cancer (NSCLC). The new drug submission was based on clinicaltrials involving more than 800 patients worldwide.

Articles in this issue
New Probe Detects Fusion of bcr/abl
Avon's Breast Cancer Crusade to Offer 'Pink Ribbon' Pens
Take a Behind the Scenes Look at ODAC
Michigan Cancer System Named for Woman
Panel Favors Approval of Gemzar for Use In Patients With Late Stage Pancreatic Cancer
High-Dose Chemo Patients to Get Stem Cells With the MDR-1 Gene
Report on Minority Health Finds Few Black Oncologists
Where Are We Going and What Questions Do We Need to Ask?
Phase I Trial of Circadian Patterned Infusion of Continuous IL-2 Opens
Hodgkin's Disease Patients Sought for Trial of MoAb
New Health Care Insurance Reform Legislation Introduced in the Senate
FDA Approves Phase II Trials of Agouron's HIV Protease Inhibitor
House committee Recommends Budget Increases for NIH, NCI
Two New Appointees at the NCI
Chemo Plus Transplant Promising For Advanced Hepatocellular Cancer
Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Related Content
Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Andrea Eleazar, MHS
December 23rd 2025
Article

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Unadjusted post-recurrence OS was numerically lower with palbociclib plus endocrine therapy vs endocrine therapy alone in the phase 3 PALLAS trial.

Palbociclib Shows No OS Difference Vs Endocrine Therapy in Breast Cancer

Riley Kandel
December 22nd 2025
Article

Unadjusted post-recurrence OS was numerically lower with palbociclib plus endocrine therapy vs endocrine therapy alone in the phase 3 PALLAS trial.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Pyrotinib Combo Sustains Survival Benefits in HER2+ Breast Cancer Trial

Russ Conroy
December 21st 2025
Article

Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Data from the PREFER study may provide evidence for improving oncofertility counseling for premenopausal women with early breast cancer.

Majority of Breast Cancer Cohort Opts for Fertility Preservation Strategies

Ryan Scott
December 21st 2025
Article

Data from the PREFER study may provide evidence for improving oncofertility counseling for premenopausal women with early breast cancer.